Related Experiment Video
Updated: Aug 21, 2026

Peptide-based Identification of Functional Motifs and their Binding Partners
Published on: June 30, 2013
Clinical aspects of endothelial dysfunction associated with human immunodeficiency virus infection and antiretroviral
Sudha S Shankar1, Michael P Dubé
1Department of Medicine and Divisions of Endocrinology, Indiana University School of Medicine, Indianapolis, IN, USA.
Insights
Human immunodeficiency virus type 1 (HIV-1) protease inhibitors (PIs) may cause endothelial dysfunction, a key step in atherosclerosis. This dysfunction is linked to lipid and glucose metabolism changes, impacting cardiovascular health in HIV patients.
Area of Science:
- Cardiovascular Science
- Infectious Disease Research
- Pharmacology
Background:
- Endothelial dysfunction is a primary event in atherogenesis, contributing to atherosclerosis progression and clinical outcomes.
- Human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI) use is linked to increased cardiovascular events and risk factors like dyslipidemia, insulin resistance, and endothelial dysfunction.
- Endothelial dysfunction in HIV patients may stem from the infection itself or antiretroviral treatment side effects.
Purpose of the Study:
- To investigate the role of HIV-1 protease inhibitors (PIs) in causing endothelial dysfunction.
- To explore the mechanisms by which PIs affect lipid and glucose metabolism, contributing to endothelial dysfunction.
- To assess the contribution of metabolic and body shape changes associated with HIV treatment-related lipodystrophy to endothelial dysfunction.
Main Methods:
- Review of available evidence on PI effects on cardiovascular risk factors.
- Analysis of studies examining endothelial function in healthy subjects treated with specific PIs (e.g., indinavir).
- Investigation into the physiological mechanisms underlying PI-induced endothelial dysfunction.
Main Results:
- Evidence suggests PIs can induce endothelial dysfunction through impacts on lipid and glucose metabolism.
- Studies confirm reduced endothelial nitric oxide production in indinavir-associated endothelial dysfunction.
- Metabolic alterations and lipodystrophy associated with HIV treatment may contribute to endothelial dysfunction.
Conclusions:
- HIV-1 PIs are implicated in causing endothelial dysfunction, a critical factor in atherosclerosis development.
- Further research is required to elucidate the mechanisms and identify effective interventions for endothelial dysfunction in HIV-infected individuals.
- Understanding the comparative effects of different antiretroviral agents on endothelial function is crucial for managing cardiovascular risk in this population.
Abstract:
Endothelial dysfunction is a critical initial step of atherogenesis that subsequently contributes to the progression and clinical manifestations of atherosclerosis. The use of human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI) agents has been associated with increased cardiovascular events and worsening of multiple coronary heart disease risk factors including dys-lipidemia, insulin resistance, and endothelial dysfunction. Endothelial dysfunction may be caused by HIV infection itself as well as treatment-related effects of the antiretroviral agents used to treat HIV. The available evidence suggests that PIs may induce endothelial dysfunction via their effects on both lipid and glucose metabolism. Studies in healthy subjects confirm a role for reduced endothelial nitric oxide production in the endothelial dysfunction associated with the PI indinavir. Further work is needed to determine the relative tendencies of other antiretroviral agents to induce endothelial dysfunction, the physiologic mechanisms involved, and the contribution of the metabolic and body shape changes associated with HIV treatment-related lipodystrophy, and to establish effective interventions for endothelial dysfunction in HIV-infected patients.
Related Concept Videos
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Sexually Transmitted Infections
Retrovirus Life Cycles
Inhibitors of Virion Maturation and Assembly
Cryptococcal Meningitis
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

